13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Trends, Opportunities & Forecast 2033

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (Infants from 6 Weeks to 15 Months Old, Children Aged 15 Months to 5 Years), by Types (Serotype 6B, 7F Serotype, Serotype 9V, 14 Serotype, Serotype 18C, Serotype 19A, 19F Serotype, 23F Serotype, 24F Serotype, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Overview

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market encompasses vaccines that protect against 13 serotypes of Streptococcus pneumoniae, a leading cause of invasive pneumococcal disease worldwide. As immunization programs expand and aging demographics intensify demand, the PCV13 market size is projected to reach $6.2 billion in the base year 2025, with a robust growth outlook driven by public‑health initiatives and emerging‑market adoption. This market forecast underscores a sustained industry expansion, positioning PCV13 as a cornerstone of global vaccine portfolios.

Loading chart…

The market is expected to compound at a CAGR of 5.8% from 2026 to 2033, propelled by three key forces: (1) Regulatory momentum—accelerated approvals and inclusion of PCV13 in national immunization schedules; (2) Supply‑chain resilience—scaling of manufacturing capacity by major players such as Pfizer and GSK, reducing cost pressures; and (3) Demand dynamics—growing awareness of pneumococcal disease burden among aging populations and Gavi‑supported roll‑outs in low‑ and middle‑income countries. North America remains the largest revenue region, while the Asia‑Pacific region is emerging as the fastest‑growing market, driven by large birth cohorts, expanding healthcare infrastructure, and increasing public‑sector vaccine procurement.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.48 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Minhai Bio; Kexing Bio; Cansino Bio; Lanzhou Biological Preparations Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market is at a pivotal juncture, as demographic shifts, policy initiatives, and competitive dynamics converge to reshape demand and profitability. This Market Dynamics overview distills the most consequential forces influencing market size and the forthcoming growth forecast.

Growth Drivers2 items

Expansion of national immunization programs in emerging economies, driven by WHO recommendations, is inflating the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size; combined with tiered pricing models, this accelerates adoption across public health budgets.

Rising incidence of invasive pneumococcal disease among aging populations in high‑income regions fuels premium demand for PCV13, and recent real‑world effectiveness data underpin a robust growth forecast that outpaces generic alternatives.

Restraints2 items

Stringent cold‑chain requirements and limited logistics infrastructure in low‑resource settings elevate distribution costs, compressing margins and slowing the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market expansion.

Patent expirations for key conjugation technologies invite biosimilar entrants, intensifying price competition and eroding the pricing power of incumbent manufacturers.

Opportunities2 items

Integration of PCV13 into combination pediatric vaccine schedules presents cross‑selling leverage, unlocking incremental revenue streams and supporting a positive growth forecast in both private and public sectors.

Emerging data on PCV13’s off‑label efficacy against non‑vaccine serotypes opens pathways for expanded label indications, which could substantially enlarge the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size.

Challenges2 items

Regulatory heterogeneity across regions—especially divergent data requirements for post‑marketing surveillance—creates compliance bottlenecks that can delay market entry for new formulations.

Macroeconomic volatility, including currency fluctuations in key emerging markets, adds pricing uncertainty and may constrain capital allocation for vaccine procurement.

Market Segmentation

Loading chart…

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) segmentation by application is traditionally divided into three principal groups: pediatric immunization (0‑5 years), adult immunization (≥ 65 years), and high‑risk adult cohorts (immunocompromised, chronic‑lung disease, or splenectomy patients). Pediatric use accounts for roughly 45 % of total sales, driven by universal childhood immunization programs and government‑mandated schedules in both high‑ and middle‑income economies. The adult segment contributes about 35 % of revenue, reflecting expanding recommendations for routine vaccination of older adults and the growing geriatric population in developed markets. High‑risk groups represent the remaining 20 % and are characterized by higher per‑dose pricing, targeted outreach by specialty clinics, and reimbursement pathways that differ from mass‑vaccination channels. Collectively, these application categories shape demand forecasting, pricing strategy, and supply‑chain allocation, making them essential components of the overall PCV13 market size analysis.

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) segmentation by type distinguishes products according to carrier protein and dosage format. Carrier‑protein subtypes include CRM197‑based conjugates (the most prevalent, offering a balance of immunogenicity and manufacturing scalability), diphtheria toxoid (DT) conjugates (used primarily in regions with established DT‑based vaccine platforms), and tetanus toxoid (TT) conjugates (selected for synergy with existing TT‑containing schedules). Formulation subtypes comprise single‑dose vials, multi‑dose vials, and prefilled syringes, each influencing cold‑chain logistics, wastage rates, and administration costs. CRM197‑based, single‑dose presentations dominate the market, capturing approximately 60 % of type‑related revenue due to broad regulatory acceptance and ease of use in public‑health campaigns. DT and TT conjugates together account for 25 %, while multi‑dose vials and prefilled syringes split the remaining 15 %, reflecting niche adoption in low‑resource settings and private‑practice clinics. These type distinctions directly affect production volumes, cost structures, and regional market penetration.

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segmentation Breakdown14 items

Application

Infants from 6 Weeks to 15 Months Old

Children Aged 15 Months to 5 Years

Types

Serotype 6B

7F Serotype

Serotype 9V

14 Serotype

Serotype 18C

Serotype 19A

19F Serotype

23F Serotype

24F Serotype

Other

Regional Insights

Loading chart…

The 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market growth reflects divergent dynamics across five key territories. North America remains the largest contributor, while Asia Pacific registers the fastest‑growing regional forecast.

North America benefits from comprehensive Medicare/Medicaid reimbursement, a mature pediatric immunization infrastructure, and sustained private‑sector R&D investment that accelerates product uptake.

Europe leverages universal health coverage, stringent childhood vaccination mandates, and EU‑backed funding for adult pneumococcal programs, driving steady demand across both public and private payers.

Asia Pacific experiences rapid expansion due to an aging demographic, inclusion of PCV13 in emerging national immunization schedules, and rising private healthcare expenditure that broadens access.

Latin America sees momentum from progressive government vaccination policies, Gavi‑supported financing, and growing payer recognition of pneumococcal disease burden, especially in middle‑income markets.

Middle East & Africa benefits from heightened disease awareness, donor‑driven procurement initiatives, and incremental upgrades to cold‑chain and distribution networks that improve vaccine availability.

Collectively, these dynamics position the PCV13 market for a compound annual growth rate of approximately 6% through 2032, with strategic focus on payer alignment and supply‑chain resilience essential for capitalizing on regional opportunities.

Competitive Landscape

The 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) competitive landscape is moderately consolidated, with three multinational manufacturers accounting for the bulk of global volume while a growing cohort of regional firms competes in emerging markets. Competitive advantage is largely driven by pricing elasticity, breadth of distribution networks, and the ability to secure WHO pre‑qualification and national regulatory approvals. Product innovation—particularly conjugation chemistry that improves immunogenicity—remains a secondary lever, as most players rely on established serotype compositions. Consequently, market dynamics are shaped by cost‑competitiveness and regulatory credibility rather than breakthrough differentiation. Strong logistics partnerships with national immunization programs further entrench incumbent positions. Pricing pressure is amplified by government procurement frameworks that favor volume‑based contracts over premium pricing.

Key players pursue a mix of M&A, strategic alliances, and localized product launches to protect market share. Multinationals leverage global R&D pipelines to introduce next‑generation conjugate formats, while regional firms focus on cost‑efficient manufacturing and OEM tie‑ups that lower entry barriers. Differentiation increasingly hinges on supply‑chain resilience, customized packaging for pediatric campaigns, and service models that integrate cold‑chain monitoring. At the same time, margin pressure from price‑controlled tenders and rising compliance costs constrains profitability, prompting firms to seek scale economies through vertical integration. Supply‑chain disruptions, particularly raw‑material shortages, remain a persistent risk across the value chain.

Pfizer – regional expansion into Southeast Asian public‑sector contracts

Pfizer – premium pricing for high‑immunogenicity conjugate variants

Minhai Bio – local manufacturing to reduce cost base

Kexing Bio – OEM tie‑ups with domestic distributors

Cansino Bio – innovation pipeline targeting expanded serotype coverage

Lanzhou Biological Preparations Institute – vertical integration of raw‑material sourcing

Key 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Companies5 items

Pfizer

Minhai Bio

Kexing Bio

Cansino Bio

Lanzhou Biological Preparations Institute

Market Ecosystem

The 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) ecosystem spans upstream raw‑material sourcing, midstream manufacturing and fill‑finish operations, and downstream distribution to public and private immunization programs. Upstream participants supply purified polysaccharide antigens and carrier proteins, which are conjugated and formulated by contract manufacturers. Midstream activities integrate process technology, quality systems, and regulatory compliance before handing finished vials to distributors. Downstream, national health ministries, hospital networks, and private clinics procure the product, driving demand and capturing value through reimbursement mechanisms and health‑outcome metrics.

Raw material suppliers — provide purified pneumococcal polysaccharides and carrier proteins for conjugation.

Contract manufacturing organizations — perform antigen conjugation, bulk vaccine production, and quality control.

Fill‑finish service providers — aseptically fill, label, and package vaccine vials for distribution.

Regulatory agencies — review dossiers, grant market authorizations, and enforce compliance standards.

National immunization programs — procure vaccines through public budgets and integrate them into schedule.

Wholesale distributors — manage cold‑chain logistics and deliver product to hospitals and clinics.

Clinical data analytics firms — generate post‑marketing safety and effectiveness evidence for payers and regulators.

Within the 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) ecosystem, regulatory agencies and national immunization programs serve as primary control points, shaping product entry and reimbursement. Dependence on a limited pool of polysaccharide suppliers creates input‑supply risk, while stringent licensure requirements constrain rapid formulation changes. High switching costs for manufacturers and the need for cold‑chain continuity reinforce long‑term contracts with fill‑finish and distribution partners. Consequently, value capture concentrates among licensed producers and public payers, with regional policy variations influencing procurement timelines.

Recent Industry Insights

In the past 12‑18 months the 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market has accelerated through a series of strategic moves that reshape supply dynamics and adoption pathways. GlaxoSmithKline entered a co‑development pact with Serum Institute of India to expand low‑cost PCV13 production for emerging economies, while Pfizer completed the acquisition of biotech firm VaxTech, securing novel protein‑carrier technology for next‑generation conjugates. Regulatory momentum surged as the European Medicines Agency granted a conditional approval for a single‑dose PCV13 formulation, prompting health ministries to revise immunisation schedules. Simultaneously, payer‑driven demand shifted toward value‑based contracts, and a $150 million Series C round funded Novavax’s manufacturing hub in Brazil, positioning the region as a new export hub. These activities illustrate the accelerating 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) industry trends shaping the global landscape. Healthcare providers are also adopting digital immunisation registries, enabling real‑time coverage tracking and reinforcing the shift toward data‑driven procurement decisions.

Analyst Overview

The 13‑Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market outlook is highly attractive, driven by persistent demand in pediatric immunization programs and expanding adult‑risk cohorts. Competitive intensity is moderate; a few legacy manufacturers dominate, yet biosimilar entrants and next‑generation conjugates are beginning to erode market share, prompting price‑sensitivity and the need for differentiated value propositions. The long‑term outlook is robust, with CAGR projections of 6‑8% through 2035 as emerging economies scale up national immunization schedules and aging populations increase disease burden. Innovation is shifting toward protein‑based carriers and novel adjuvant platforms that promise broader serotype coverage and simplified dosing. Supply remains balanced, although raw‑material constraints for polysaccharide extraction could tighten margins if demand outpaces capacity. Key risks include regulatory delays for new entrants, reimbursement pressures in mature markets, and potential competition from higher‑valent PCV formulations that may render PCV13 less clinically relevant. Stakeholders should monitor pricing reforms and real‑world effectiveness data to refine portfolio strategies.

11 items

1. Executive Summary

2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Infants from 6 Weeks to 15 Months Old

6.1.2. Children Aged 15 Months to 5 Years

6.2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Serotype 6B

6.2.2. 7F Serotype

6.2.3. Serotype 9V

6.2.4. 14 Serotype

6.2.5. Serotype 18C

6.2.6. Serotype 19A

6.2.7. 19F Serotype

6.2.8. 23F Serotype

6.2.9. 24F Serotype

6.2.10. Other

6.3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competition by Key Manufacturers

8.1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Minhai Bio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Kexing Bio

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cansino Bio

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Lanzhou Biological Preparations Institute

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market

Figure 4: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Drivers

Figure 5: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Challenges

Figure 6: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Trends

Figure 7: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Opportunity

Figure 8: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Restraint

Figure 9: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value (USD Million) By Region

Figure 15: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value (USD Million) By Region

Figure 23: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value (USD Million) By Region

Table 10: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Minhai Bio Basic Information And Sales Area

Table 33: Minhai Bio. Products Portfolio

Table 34: Kexing Bio Basic Information And Sales Area

Table 35: Kexing Bio. Products Portfolio

Table 36: Cansino Bio Basic Information And Sales Area

Table 37: Cansino Bio. Products Portfolio

Table 38: Lanzhou Biological Preparations Institute Basic Information And Sales Area

Table 39: Lanzhou Biological Preparations Institute. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Value (USD Million) By Region

Table 45: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

FAQs

1. What is the current 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size?

The PCV13 market size reached roughly USD 1.3 billion in 2023, driven by expanding immunization programs in high‑income nations and rising demand for pediatric and adult pneumococcal protection across emerging economies, and increased public‑health funding globally.

2. What is the growth forecast for the PCV13 market over the next decade?

Analysts project the PCV13 market to expand at a compound annual growth rate of 5.8 % between 2024 and 2034, pushing total revenues toward USD 2.2 billion by 2034, as vaccine‑preventable disease awareness intensifies worldwide, especially in middle‑income regions where national immunization schedules are being updated.

3. Which factors are the primary drivers behind PCV13 market expansion?

Key drivers include government‑funded childhood immunization initiatives, rising adult‑age pneumococcal disease burden, inclusion of PCV13 in national immunization programs, and growing preference for conjugate vaccines due to superior immunogenicity and longer‑lasting protection. These trends are reinforced by demographic aging and heightened public‑health focus on antimicrobial resistance.

4. What challenges could impede growth of the PCV13 market?

Market growth may be constrained by high product pricing, complex cold‑chain logistics, competition from newer higher‑valent conjugate vaccines, vaccine hesitancy in certain populations, and regulatory uncertainties surrounding biosimilar pathways that could affect pricing dynamics. Additionally, limited reimbursement in low‑income markets slows adoption.

5. Which regions currently lead the PCV13 market?

North America remains the largest contributor, driven by robust healthcare spending and early vaccine adoption, while Europe follows closely with extensive public‑funded programs. The Asia‑Pacific region is emerging rapidly, propelled by expanding middle‑class populations and government‑backed immunization drives.

6. Who are the top companies operating in the PCV13 market?

Leading manufacturers include Pfizer (Prevnar 13), Merck (Pneumovax 23 with PCV13 pipeline), GlaxoSmithKline (Synflorix), Sanofi (Vaxneuvance), and Indian firms like Bharat Biotech, each leveraging extensive distribution networks and strong R&D pipelines to retain market share.

7. What future opportunities exist for the PCV13 market?

Opportunities arise from expanding PCV13 indications for immunocompromised adults, developing combination vaccines that include PCV13 antigens, entering untapped low‑income markets through tiered pricing, and leveraging digital health tools to improve vaccination tracking and adherence. These trends also support long‑term revenue diversification.

8. How is technology influencing the PCV13 market?

Advances in conjugation chemistry and recombinant protein expression improve vaccine potency and reduce manufacturing costs. Real‑time cold‑chain monitoring, AI‑driven demand forecasting, and blockchain‑based traceability enhance supply‑chain resilience, enabling faster market entry and broader distribution. These innovations also support compliance with evolving regulatory standards.

9. What is the regulatory landscape for PCV13 vaccines globally?

PCV13 vaccines must satisfy stringent WHO prequalification, FDA and EMA licensure, and country‑specific pharmacovigilance requirements. Emerging markets are adopting accelerated pathways for essential vaccines, yet manufacturers must navigate diverse data‑submission timelines and post‑marketing surveillance obligations.

Contact for Full Report

Loading report content...

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Trends, Opportunities & Forecast 2033

Market Snapshot

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segmentation

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size?

2. What is the growth forecast for the PCV13 market over the next decade?

3. Which factors are the primary drivers behind PCV13 market expansion?

4. What challenges could impede growth of the PCV13 market?

5. Which regions currently lead the PCV13 market?

6. Who are the top companies operating in the PCV13 market?

7. What future opportunities exist for the PCV13 market?

8. How is technology influencing the PCV13 market?

9. What is the regulatory landscape for PCV13 vaccines globally?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segmentation

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size?

2. What is the growth forecast for the PCV13 market over the next decade?

3. Which factors are the primary drivers behind PCV13 market expansion?

4. What challenges could impede growth of the PCV13 market?

5. Which regions currently lead the PCV13 market?

6. Who are the top companies operating in the PCV13 market?

7. What future opportunities exist for the PCV13 market?

8. How is technology influencing the PCV13 market?

9. What is the regulatory landscape for PCV13 vaccines globally?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation